Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medrx CoTSE:4586 +3.64%57 Gross Margin % is 0.00% as of Dec. 2025. GuruFocus rates TSE:4586 with a GF Score™ of 57/100 and a GF Value™ of 円70.55 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 943 Drug Manufacturers companies, Medrx Co ranks better than 99.58% on this metric.
The historical rank and industry rank for Medrx Co's Gross Margin % or its related term are showing as below:
TSE:4586'
s Gross Margin % Range Over the Past 10 Years
Min: 66.06 Med: 96.03 Max: 99.88
Current: 98.43
During the past 13 years, the highestGross Margin % of Medrx Co was 99.88%. The lowest was 66.06%. And the median was 96.03%.
TSE:4586's Gross Margin % is ranked better than 99.58% of 943
companies
in the Drug Manufacturers industry
Industry Median: 48.54
vs TSE:4586: 98.43
Medrx Co had a gross margin of N/A% for the quarter that ended in Dec. 2025 => No sustainable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Medrx Co was 3.00% per year.
Medrx Co (TSE:4586) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Medrx Co had a gross margin of N/A% for the quarter that ended in Dec. 2025 => No sustainable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Medrx Co Gross Margin % Related Terms
Medrx Co Gross Margin % Historical Data
* Premium members only.
The historical data trend for Medrx Co's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Medrx Co's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medrx Co Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Medrx Co's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Medrx Co's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Medrx Co (TSE:4586) has a Gross Margin % of 0.00% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Medrx Co and its competitors. Over the past decade, Medrx Co's Gross Margin % has ranged from 66.06 to 99.88. According to the industry distribution chart, Medrx Co ranks #4 out of 943 companies in the Drug Manufacturers industry, placing it in the top 0.40000000000001%.
Is Medrx Co's Gross Margin % too high?
Medrx Co's current Gross Margin % is 0.00%. Over the past 10 years, this metric has ranged from a low of 66.06 to a high of 99.88. Based on the distribution chart, Medrx Co ranks #4 out of 943 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Medrx Co has a GF Score™ of 57/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medrx Co's Gross Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Medrx Co ranks #4 out of 943 companies for Gross Margin %. This places Medrx Co in the top 0% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 48.54. Historically, Medrx Co's own Gross Margin % has ranged from 66.06 to 99.88 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.54, based on 943 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Medrx Co and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medrx Co's current Gross Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medrx Co stock overvalued right now?
Based on GuruFocus' analysis, Medrx Co (TSE:4586) is currently considered Modestly Undervalued. The stock's GF Value™ is 円70.55, compared to a current price of 円57.00 — trading 19.2% below its estimated fair value. The current Gross Margin % is 0.00%. Medrx Co's overall GF Score™ is 57/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Medrx Co (TSE:4586), the current Gross Margin % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medrx Co (TSE:4586) Overvalued in 2026?
Based on GuruFocus' analysis, Medrx Co stock appears to be undervalued.
The current stock price of 円57.00 is trading 19.2% below its estimated GF Value™ of 円70.55.
GuruFocus considers Medrx Co to be Modestly Undervalued.
Key valuation signals for TSE:4586:
Gross Margin %: 0.00%
GF Value™: 円70.55 vs. price of 円57.00 (19.2% below fair value)
No single metric tells the full story. See the TSE:4586 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medrx Co Ltd is a pharmaceutical drug development company founded in January, 2002. The Company engaged in the research and development of pharmaceutical products utilizing the pharmaceutical formulation technology based on ionic liquid transdermal system. The Company develops new pharmaceutical candidates and licenses other companies to produce the pharmaceuticals after clinical trials. Its main products include analgesic patches for anti-inflammatory and pain relief.
57GF Score
Get the complete analysis for TSE:4586
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4586 has been successfully added to your 
